Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SF-2 gp120
- Development stage
- Phase 2
- Lead developer
- Novartis
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
SF-2 gp120 is a recombinant form of the surface envelope glycoprotein (gp120) of the Human Immunodeficiency Virus Type 1 (HIV-1), specifically derived from the SF-2 strain. It was developed as a candidate subunit vaccine for the prevention of HIV/AIDS. Produced using recombinant DNA technology, typically in Chinese Hamster Ovary (CHO) cells, this protein mimics the viral component responsible for binding to CD4 receptors on host T-cells. The vaccine is intended to elicit neutralizing antibodies and cell-mediated immune responses. In clinical trials, SF-2 gp120 was often evaluated in combination with novel adjuvants, such as MF59 (a submicron oil-in-water emulsion) and MTP-PE, to enhance its immunogenicity, which is generally limited when the protein is administered alone.
- Brand names
- BIOCINE
- Other names
- Recombinant HIV-1 SF2 gp120HIV-1 SF2 envelope glycoprotein gp120HIV1 SF2 envelope glycoprotein gp120HIV 1 SF2 envelope glycoprotein gp120gp120 SF2gp-120 SF2gp 120 SF2
02
Targets
CD4 (T lymphocyte surface antigen)α4β7 (Integrin alpha-4 beta-7 heterodimer)
Beyond the preview
Go deeper on SF-2 gp120.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SF-2 gp120.